The aetiology of ischemic heart diseases is mainly based on atherosclerosis of coronary artery. Inflammation and oxidative reactions are initiating and aggravating the illness resulting in pathological remodelling of vasculaturze at site of injury. Endothelium lining of blood vessels participated in the reaction biochemically through releasing some proteins into circulatory system which further complicate the condition. The aim of this study was to determine early diagnosed hyperlipidaemia-associated changes of the plasma level of some of these endothelial biomolecules. Compared to healthy control, hyperlipidaemic patients have significantly increased arginase, metalloendopeptidase, peroxidase, myeloperoxidase, and peroxynitrite with concomitant reduction in arylesterase and nitric oxide. The present study concluded that hyperlipidaemia play a great role in modulation of certain plasma protein markers which might be directly related to patient pathological condition or could be used as a tool for diagnosis or patient follow up indicating the stage of vasculature remodelling, healing, inflammation or resolution.

It is known that there is a strong association between oxidative stress and insulin resistance in type 2 diabetes mellitus (T2DM). Although the role of glibenclamide in diabetes treatment has been evaluated, there is only limited evidence about its antioxidant effects in diabetic patients. Moreover, previous studies showed discrepant results regarding the effects of metformin on antioxidant/ oxidant parameters in type 2 diabetic patients. The present study aimed to evaluate the effects of metformin versus glibenclamide on oxidative stress biomarkers, represented by serum malondialdehyde (MDA), nonenzymatic, and enzymatic antioxidants in type 2 diabetic patients. Forty-six patients with T2DM participated in this study and categorized into 3 groups, Group A included 17 newly diagnosed diabetic patients, group B included 15 diabetic patients received metformin monotherapy (1000 mg/day) for up to 1 year and group C included 14 diabetic patients received glibenclamide monotherapy (5 mg/day) for up to 1 year. Serum MDA, catalase (CAT), vitamin C, E, and reduced glutathione (GSH) were measured. We found significantly lower concentrations of MDA and significantly higher antioxidant levels (CAT, GSH, vitamin C, and E) in the metformin-treated group compared to the glibenclamide counterpart. Our data confirmed that metformin has a more beneficial effect on oxidant/antioxidant status compared to glibenclamide, therefore, provides protection against reactive oxygen species (ROS) induced oxidative damage during diabetes.

Type 1 diabetes (T1DM) is well recognized risk factor cardiovascular disease (CVD). Insulin therapy is recommended for all patients with type 1 diabetes. Previous findings showed that diabetes impairs endothelial function and increased glucose level reduces nitric oxide (NO) output and increases myeloperoxidase (MPO) activity. However, adiponectin (APN) decreases serum glucose levels. The current study evaluated effects of insulin therapy on circulating levels of oxidative stress and CVD biomarkers like NO, APN, MPO, AIP and lipid profile in type 1 diabetic patients. Fifty patients with T1DM and 18 healthy people were enrolled in this study. The recruited people with T1DM were classified into two groups: 22 newly diagnosed (untreated) type 1 diabetic patients and 28 insulin treated patients. In all groups, circulating NO, APN, MPO, AIP and lipids levels were measured. Compared to control, untreated diabetes revealed a significant increase in the serum levels of APN, MPO, TG, VLDL, TC, LDL and AIP, with a marked reduction in NO and HDL levels. However, insulin therapy significantly lowered MPO, TC and LDL, with no significant changes in the other biochemical parameters. As expected, oxidative stress and CVD-associated markers were significantly increased in untreated diabetes. Insulin therapy exhibited a relatively positive effect on oxidative stress and CVD biomarkers. Accordingly, insulin plus antioxidant supplementation required to normalize these parameters.

The research included an estimation of the concentration of obestatin hormone level in diabetic patients (Type I and Type II) and control. The results demonstrated that the normal mean of obestatin hormone in serum was (306.54 ± 3.0pg/ml) in control for both sexes, with the ages range between (less or equal to 15-more or equal to 55) year. The results demonstrated a significant decrease in the level of obestatin hormone in serum of type I and type II diabetic patients compared to control, and between types I & II diabetic patients. The data showed that the level of obestatin hormone was not affected by age and sex, in control and diabetic patients, while showed a significant decrease according to body mass index (BMI) in control and diabetic patients (Type I and II). A significant gradual decrease in the concentration of obestatin as glucose concentration increases in diabetic patients was also observed. The results showed a significant increase of adiponectin concentration between type I diabetic patient compared to type II, control, and a significant decrease in the concentration of adiponectin in diabetic patients (type II) compared with control. Correlation coefficients of obestatin hormone with some biochemical parameters of control and diabetic patients showed that obestatin hormone has a significant negative correlation with glucose, HOMA-IR, total cholesterol and LDL-C. Also, there was a significant positive correlation with HDL-C and adiponectin in control and diabetic patients (type I and II). The result showed that obestatin hormone has a significant negative correlation with insulin, VLDL-C, total lipids in type II diabetic patients. Also, with triglyceride in control and type II diabetic patient. It was concluded that low level of obestatin hormone index is a serious risk of diabetes mellitus and a major role for obestatin in diabetes mellitus type II. Moreover, the level could be used as a marker for diabetes mellitus and its role in obesity.

Earlier works have revealed increased generation of reactive oxygen species (ROS) and decreased antioxidant levels in type 1 diabetes mellitus (T1DM). The current study aimed to investigate the effect of mixed insulin therapy on oxidative stress and antioxidant status in patients with T1DM. This study involved 75 participants who were divided into three groups: 20 healthy subjects as a control, 25 newly diagnosed patients with T1DM (without treatment) and 30 patients with T1DM treated with insulin (regular and Human Neutral Protamine Hagedorn (NPH)) twice daily. Fasting serum glucose (FSG), serum concentrations of insulin, malondialdehyde (MDA), catalase (CAT), reduced glutathione (GSH), and vitamins (C and E) were measured in all participants. Compared with the healthy control, serum glucose and MDA concentrations were observed to be significantly higher, while significantly lower concentrations of CAT, GSH, and vitamins (C and E) were found in both the treated and untreated diabetic groups. Although insulin therapy caused a significant decrease in blood sugar with a marked elevation in the levels of insulin, CAT, GSH and vitamin E compared to the untreated patients, the changes in the levels of MDA and vitamin C between diabetic groups were not significant. Moreover, the level of insulin resistance was significantly increased in insulin-treated patients as compared to the control and untreated diabetic groups. In conclusion, twice daily treatment with regular and NPH insulin can ameliorate hyperglycemia and improve antioxidant levels in patients with T1DM. However, the insulin regimen used in this study did not reveal a beneficial effect on oxidative stress and insulin resistance. Hence, exogenous antioxidants (vitamins C and E) can be used in combination with insulin to control these parameters.

Metformin and glibenclamide may have beneficial effects on the levels of trace elements in diabetic patients. The aim of the current study was to assess the effects of metformin and glibenclamide on the concentrations of copper (Cu), zinc (Zn) and magnesium (Mg) in patients with type 2 diabetes mellitus. The metformin-treated patients showed significantly lower serum Cu levels compared with the untreated and glibenclamide groups. In addition, treatment with metformin was associated with a significant increase in serum concentrations of Zn compared to the newly diagnosed patients, whereas it did not show a noticeable alteration in the serum level of Mg. In contrast, the glibenclamide treated group revealed significantly higher Zn and Mg levels compared with the newly diagnosed group, while the serum level of Cu was not significantly modified. In conclusion, treatment with metformin led to a reduction in serum Cu and an increase in serum Zn concentrations, whereas glibenclamide treatment displayed enhancement in serum Zn and Mg levels.

No abstract

The study included an attempt to isolate and purify obestatin from healthy human plasma using different biochemical techniques. Two proteinous peaks had been isolated by gel filtration chromatography (Sephadex G-50) from the precipitate produced by precipitation using cold acetone. It was found that the second peak (peak B) only had an obestatin. Two proteinous components had also been isolated by the same technique using Sephadex G-25 from the peak B. It was found that the second peak (peak D) had a high concentration of obestatin. Furthermore, the purity of the isolated obestatin (peak D) had been identified by the reversed phase high performance liquid chromatography and by SDS-polyacrylamide gel electrophoresis technique. The results obtained from the RP-HPLC showed that there was a good identity in retention time between the standard and the isolated obestatin (peak D). The approximate molecular weight of partially purified obestatin was (2573 ± 100 Da) and (2660 Da) using gel filtration chromatography by Sephadex G-25 and (SDS-PAGE) technique respectively. The effect of the isolated obestatin (peak D) on some biochemical parameters in normal and alloxan induced diabetic male rats had been studied. After one week of treatment, the results showed that the obestatin at the dose (1 µmol / kg of body weight / d) caused a significant decrease in the levels of glucose, total lipids, total cholesterol, triglycerides, LDL-C, VLDL-C and MDA, in a addition to a significant increase in the levels of HDL-C in normal and alloxan induced diabetic rats and GSH in alloxan induced diabetic rats. It was concluded that the isolated obestatin from plasma had a an important role in metabolism of glucose and lipid profile in normal and alloxan induced diabetic rats.